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Insulin resistance is a defining feature of metabolic
syndrome and type 2 diabetes mellitus but also may
occur independently of these conditions. Nonalco-
holic fatty liver disease (NAFLD), the hepatic manifes-
tation of these disorders, increases the risk of hepa-
tocellular carcinoma (HCC). However, mechanisms
linking hyperinsulinemia to NAFLD and HCC require
clarification. We describe a novel model of primary
insulin resistance and HCC with strong parent-of-or-
igin effects. Male AB6F1 (A/JCr dam  C57BL/6 sire)
but not B6AF1 (B6 dam  A/J sire) mice developed
spontaneous insulin resistance, NAFLD, and HCC
without obesity or diabetes. A survey of mitochon-
drial, imprinted, and sex-linked traits revealed mod-
est associations with X-linked genes. However, a diet-
induced obesity study, including B6.A chromosome
substitution–strain (consomic) mice, showed no seg-
regation by sex chromosome. Thus, parent-of-origin
effects were specified within the autosomal genome.
Next, we interrogated mechanisms of insulin-associ-
ated hepatocarcinogenesis. Steatotic hepatocytes ex-
hibited adipogenic transition characterized by vacuo-
lar metaplasia and up-regulation of vimentin, adipsin,
fatty acid translocase (CD36), peroxisome prolifera-
tor–activated receptor-, and related products. This
profile was largely recapitulated in insulin-supple-
mented primary mouse hepatocyte cultures. Impor-
tantly, pyruvate kinase M2, a fetal anabolic enzyme
implicated in the Warburg effect, was activated byinsulin in vivo and in vitro. Thus, our study reveals
parent-of-origin effects in heritable insulin resis-
tance, implicating adipogenic transition with ac-
quired anabolic metabolism in the progression from
NAFLD to HCC. (Am J Pathol 2011, 179:2855–2865; DOI:
10.1016/j.ajpath.2011.08.014)
Metabolic diseases, such as obesity, insulin resistance,
metabolic syndrome, and type 2 diabetes mellitus (T2D),
are reaching epidemic proportions.1 Serious comorbidi-
ties are associated with these conditions, including hy-
pertension, cardiovascular disease, and increased risk
for several types of cancer.2,3 Nonalcoholic fatty liver
disease (NAFLD), the hepatic manifestation of this group
of disorders, increases the risk of hepatocellular carci-
noma (HCC).4 HCC is the third leading cause of cancer
deaths worldwide and the fastest increasing cancer in
the United States.5 In a recent prospective study of
asymptomatic, middle-aged adults from the United
States, the prevalence of NAFLD as determined by ultra-
sonography and/or biopsy was found to be 46%.6 Nonal-
coholic steatohepatitis (NASH), the more serious NAFLD
subcategory defined by hepatic steatosis, inflammation,
and ballooning degeneration, afflicts 12% of middle-
aged Americans.6 As a result, NAFLD (specifically,
NASH) may one day surpass hepatitis C virus infection as
the leading cause of HCC in this country.
Genetic predisposition contributes to HCC risk on a
metabolic background, but molecular markers of preneo-
plastic progression and hepatocellular transformation re-
main elusive. Moreover, because of extensive overlap in
clinical presentation, it is difficult to ascribe hepatic con-
sequences, such as NAFLD and HCC, to specific meta-
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atopathy are ill-equipped to address these questions
because most exhibit obesity, insulin resistance, and/or
T2D as part of a disease continuum. New models are
needed to dissect the roles of individual metabolic pa-
rameters in the pathogenesis of hepatic steatosis and
carcinogenesis. We describe a novel mouse model of
primary insulin resistance and NAFLD leading to HCC in
the absence of obesity or T2D. Intriguingly, the model
exhibits strong parent-of-origin effects encoded predom-
inantly within the autosomal genome, suggesting involve-
ment of imprinted genetic elements that may serve as useful
biomarkers and/or interventional targets. We used this
model to probe mechanisms of hyperinsulinemic NAFLD
and HCC and documented adipogenic transition of hepa-
tocytes with reactivation of the anabolic enzyme pyruvate
kinase M2 (PKM2), a fetal metabolic marker associated
with the Warburg effect.7 Taken together, our results sug-
gest that epistatic interactions between parent-specific
loci play an important role in regulating insulin sensitivity
and that hepatocellular adipogenic transition with ac-
quired anabolic metabolism represents a potential mech-
anistic link between NAFLD and HCC.
Materials and Methods
Animals and Study Design
A/JCr mice (A/J) were purchased from the National Can-
cer Institute (Frederick, MD). C57BL/6J (B6) and B6.A
chromosome substitution-strain (CSS; consomic) mice
were obtained from the Jackson Laboratory (Bar Harbor,
ME). Experiments were performed in facilities accredited
by the Association for Assessment and Accreditation of
Laboratory Animal Care. Mice were maintained in static
microisolator cages under specific pathogen-free condi-
tions for 11 murine viruses, Helicobacter spp., Salmonella
spp., Citrobacter rodentium, ectoparasites, and endo-
parasites. Helicobacter-free status was confirmed by
DNA PCR on pooled cage feces.8 In the first experiment,
A/J and B6 mice were intercrossed and parent-of-origin
records maintained to identify offspring as AB6F1 or
B6AF1. All F1 offspring (n  59) were fed the same rodent
chow diet (Prolab RMH 3000; Scott’s Distributing, Hud-
son, NH) and collected at 3, 9, or 15 months of age. In a
follow-up diet-induced obesity (DIO) study, A/J, C57BL/
6J-Chr XA/J/NaJ (B6.AX), C57BL/6J-Chr YA/J/NaJ (B6.AY),
AB6F1, and B6AF1 mice were raised under standard
conditions until 6 weeks of age and then randomly as-
signed into low-fat (LF) or high-fat (HF) diet groups (min-
imum of 8 animals per sex per group, n  207). The LF
diet contained 10 kcal percentage of fat and the HF diet
60 kcal percentage of fat (catalog numbers D12450B and
D12492; Research Diets, New Brunswick, NJ). Mice were
maintained on the LF or HF diet for 12 weeks. Mice in
both studies were euthanatized via carbon dioxide inha-
lation according to recommendations of the AVMA Panel
on Euthanasia. Protocols were compliant with the US
Public Health Service Policy on Humane Care and Use of
Laboratory Animals and approved by the MassachusettsInstitute of Technology Committee on Animal Care and
University of North Carolina Institutional Animal Care and
Use Committee. Body weight was recorded and blood
collected via cardiac puncture immediately after eutha-
nasia. Full necropsies were performed and blood and
tissues collected per our published protocols.9,10
Blood and Tissue Analyses
Blood glucose concentrations were obtained using the
One Touch Basic Glucometer (LifeScan, Milpitas, CA).
Cholesterol concentrations were measured with the Ac-
cutrend GC (Roche Diagnostics, Branchburg, NJ). Se-
rum insulin concentrations were determined with the Lin-
coplex rat/mouse insulin enzyme-linked immunosorbent
assay kit (Millipore, Billerica, MA). The homeostatic
model of assessment for insulin resistance was calcu-
lated as previously described.11 Parametric laboratory
data among all groups were compared by one-way anal-
ysis of variance with Tukey’s posttest and between pairs
by Student’s t-test using Prism software (GraphPad, San
Diego, CA). P  0.05 was considered significant. H&E-
stained slides of liver were graded by a board-certified
veterinary pathologist (A.B.R.) masked to sample identity
for hepatic steatosis based on semiquantitative percent-
age of centrilobular and midzonal hepatocytes contain-
ing lipid vacuoles, with 0 indicating less than 5% of hepa-
tocytes; 1, 5% to 25%; 2, 25% to 50%; 3, 50% to 75%;
and 4, more than 75%. Macrovesicular and microvesicu-
lar steatosis were scored separately according to pub-
lished morphologic criteria. The combined scores were
added to generate a fatty liver index. Inflammation and
dysplasia or neoplasia also were scored according to our
published criteria.9 Nonparametric histopathology scores
were compared among all groups by Kruskal-Wallis anal-
ysis of variance with Dunn’s posttest and between pairs
by the Mann-Whitney U-test. Frozen liver sections in OCT
medium were cryosectioned and stained with Oil Red O
for lipids. Immunohistochemistry for PKM2 (antibody
3198; Cell Signaling Technology, Beverly, MA) was per-
formed on a Bond-III immunostainer (Leica, Bannock-
burn, IL) following techniques we have previously pub-
lished.12
Gene Expression Analysis
mRNA was isolated from liver and assessed for quality as
we have previously described.13 Tissues from two
9-month-old, male AB6F1 and B6AF1 mice were ana-
lyzed using the Mouse Genome 430A 2.0 Array (Af-
fymetrix, Santa Clara, CA). Data were imported into
Partek Genomics Suite (Partek, St. Louis, MO) using Ro-
bust Multichip Average and normalized by response vari-
able. Data were filtered by presence or absence call by
default Affymetrix algorithms, and P value (0.05). Sig-
nal-fold changes of 1.5 or greater were considered sig-
nificant. The complete data set was deposited in the NIH
Gene Expression Omnibus (number GSE26225). Results
for selected genes were validated and extended across
all groups by SYBR Green quantitative RT-PCR (qRT-
PCR) as described previously.14 Primers were designed
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Unique primer sequences are presented in Table 1; all
others as described by Amador-Noguez et al.15
Primary Hepatocyte Isolation and Culture
Primary mouse hepatocytes were derived from collage-
nase-digested, 8-week-old, male, B6 mouse livers and
isolated and cultured following protocols described else-

























































Tnfa 5=-GCAGGTTCTGTCCCTTTCACTCAC-3=where with minor modification.16 Briefly, murine liverswere sequentially perfused in situ with 25 mL of calcium-
free EGTA-containing buffer followed by 50 mL of buff-
ered saline containing 0.3 mg/mL of type IV collagenase
(Roche Diagnostics Corp, Indianapolis, IN) at 37°C. After
perfusion, collagenase-treated livers were dissociated by
mincing with scissors followed by passage through a
100-m-pore nylon mesh. Hepatocytes were purified via
repeated (three times) low-speed (50  g) centrifugation.



























































fluorescence-assisted cell sorting. For the latter, 1  105
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AJP December 2011, Vol. 179, No. 6cells were labeled with anti-CD45/leukocyte-common an-
tigen or anti-Fas (CD95) antibodies (or appropriate con-
jugated isotype control antibodies; all from eBioscience,
San Diego, CA) for 30 minutes at room temperature fol-
lowed by evaluation on an Accuri C6 Flow Cytometer
(Ann Arbor, MI). Purified hepatocytes were grown on
collagen I–coated matrices (BD Biocoat; BD Biosci-
ences, Franklin Lakes, NJ) in Dulbecco’s modified Eagle
medium with 10% fetal bovine serum, penicillin-strepto-
mycin, and 2 mmol/L L-glutamine. Subsets of cells were
supplemented with insulin (5 mg/L), transferrin, and se-
lenium with or without dexamethasone (10 mmol/L; both
Sigma, St. Louis, MO). After 1 or 4 days, cells were
harvested and RNA isolated followed by qRT-PCR as
described above. Cell viability was determined using a
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bro-
mide kit according to the manufacturer’s instructions
(Molecular Probes, Eugene, OR). For assessment of he-
patocyte morphologic characteristics, cell suspensions
were dropped onto silanized glass slides, fixed in chilled
acetone for 10 minutes, and stained with Diff-Quik (Fisher
Scientific, Pittsburgh, PA).
Results
Insulin Resistance Without Obesity or T2D in
AB6F1 Male Mice
We characterized the phenotype of AB F1 mice fed a
standard rodent chow diet for 3, 9, or 15 months. First,
body and liver weights were determined. AB6F1 male
mice weighed 15% to 23% more than age-matched
B6AF1 controls when compared across time points
(Figure 1). Although this difference was statistically sig-
nificant, AB6F1 mice were not morbidly obese and could
not be visually distinguished from B6AF1 male mice. Fe-
male AB6F1 mice also weighed slightly more than B6AF1
female mice, but the difference was statistically insignif-
icant (not shown). AB F1 mice of both sexes weighed
more than published mean body weights for either pa-
rental inbred strain (Mouse Phenome Database; Jackson
Laboratory). Thus, hybrid mice were larger than parental
strains, but morbid obesity was not a component of the
F1 phenotype. At necropsy, it was noted that the livers of
many male mice were enlarged and pale. Absolute liver
weight and liver:body weight ratios were found to be
greater in AB6F1 than B6AF1 male mice at 9 and 15
months (Figure 1). Male AB6F1 mice had significantly
increased serum insulin levels relative to B6AF1 male
mice at all time points. Nevertheless, despite increased
serum insulin levels in AB6F1 male mice, no significant
differences were found in mean blood glucose concen-
tration between any groups regardless of sex or time
point (not shown). Moreover, no animals developed
polyuria, polydipsia, hyperphagia, and/or body wast-
ing characteristic of diabetes.17 Thus, despite high
circulating insulin levels, AB6F1 mice did not exhibit
obesity or T2D. These results demonstrate that AB6F1
but not B6AF1 male mice develop spontaneous hyper-
insulinemia on a standard chow diet and that this in-sulin resistance is not associated with morbid obesity,
metabolic syndrome, or T2D.
Hyperinsulinemic NAFLD and HCC in AB6F1
Male Mice
Masked histopathologic assessment of livers from AB
F1 mice revealed mild-to-moderate hepatic steatosis in a
subset of animals by 3 months of age, marked steatosis
by 9 months, and severe steatosis with dysplasia and/or
HCC by 15 months. When the results were decoded, it
was confirmed that the most significant lesions arose in
hyperinsulinemic AB6F1 male mice (Figure 2A). B6AF1
male mice showed no or minimal liver lesions at 3 and 9
months of age. However, 50% of BA6F1 male mice ex-
hibited mild-to-moderate steatosis at 15 months. In
AB6F1 male mice, histologic changes characteristic of
insulin resistance were identified in tissues besides the
liver as well. These changes included WAT degeneration
with F4/80 pericellular macrophages forming crown-like
rosettes, thoracic BAT metaplasia to a WAT phenotype,
focal skeletal muscle degeneration with fatty replace-
ment, and pancreatic islet hyperplasia with occasional
megaislets (Figure 2B). Within the liver, preneoplastic
and neoplastic lesions, including foci of cellular altera-
tion, dysplastic nodules, and HCC, were limited to AB6F1
male mice (incidence of 30% versus 0% in BA6F1; Figure
2C). This finding is significant because spontaneous
HCC is rare in wild-type (WT) A/J and B6 strains within the
Figure 1. Clinical metabolic parameters in AB6F1 versus B6AF1 male mice.
AB6F1 male mice developed early and progressive insulin resistance and
hepatic steatosis (fatty liver). Although AB6F1 male mice also had moderately
increased body mass compared with B6AF1 mice, neither morbid obesity nor
hyperglycemia (not shown) was a component of the phenotype. *P  0.05
compared with age-matched B6AF1 mice.typical 24-month lifespan (Mouse Phenome Database).
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AJP December 2011, Vol. 179, No. 6Figure 2. Histopathologic and genomic comparison of AB6F1 versus B6AF1 male mice. A: AB6F1 male mice exhibited more severe fatty liver lesions than B6AF1 male mice
at all time points; lipid-filled vacuoles were verified by Oil Red O staining of frozen sections; immunohistochemical demonstration of PKM2 in AB6F1 neoplastic hepatocytes but
not B6AF1 normal tissue. B: AB6F1 liver demonstrating focus of cellular alteration and dysplasia characterized by marked pleomorphism, intranuclear pseudoinclusions (arrow)
and oval cell hyperplasia (arrowheads; left); HCC arising on a background of metabolic hepatopathy (right). C: Survey of nonhepatic, insulin resistance–associated histologic
lesions in AB6F1 male mice, including WAT degeneration with macrophage proliferation forming F4/80 crown-like rosettes, metaplasia of thoracic BAT to a WAT phenotype,
focal skeletal muscle degeneration with fatty replacement, and pancreatic hyperplasia with occasional megaislets. D: Microarray heat map demonstrating hierarchal clustering of
AB6F1 versus B6AF1 male mice at 9 months. E: Histologic comparison of macrovesicular steatosis with WAT (top) and microvesicular steatosis with BAT (bottom), consistent
with transcriptional alterations characteristic of adipogenic transition. Original magnification: 100 (A); 400 (A, bottom); 400 (B, left); 40 (B, right); 200 (C); 400 (E).
right).
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with tumors of the pancreas and lower bowel,18,19 we
examined those organs grossly and histologically but
found no neoplastic or preneoplastic lesions (not shown).
The findings of histopathologic analysis of female mouse
tissues, including the liver, were unremarkable. These
findings are consistent with the male predominance of
metabolic and neoplastic liver disease documented in
humans and other rodent models.6,20 Viewed together
these results demonstrate that hyperinsulinemia, in the
absence of morbid obesity, metabolic syndrome, or T2D,
is sufficient to induce HCC in mice.
NAFLD-Associated Cytokine Induction, Acute-
Phase Responses, and Hepatic Feminization
To determine the global impact of hepatic steatosis on
gene expression, we performed microarray analysis of
liver samples from 9-month-old, male AB6F1 and
B6AF1 mice. Hierarchal clustering analysis using
Partek Genomics Suite demonstrated clear segrega-
tion of the two genotypes (Figure 2D). Four interrelated
pathophysiologic processes were evident in the stea-
totic male AB6F1 liver: inflammation, acute-phase re-
sponses, transcriptional feminization, and metabolic
Table 2. Top 10 Up- and Down-Regulated Liver Genes in AB6F1
Gene symbol Gene
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factors, histocompatibility 2 class II antigens, and oth-
ers (top 10 altered genes are listed in Table 2; com-
plete data set available at Gene Expression Omnibus
number GSE26225). Acute-phrase response induction
was confirmed by the up-regulation of canonical acute-
phase murine gene products, including lipocalin 2,
serum amyloid A1 and A2, orosomucoid, and metallo-
thioneins 1 and 2.13 Of note, all of these transcriptional
changes occurred in the absence of histologic hepati-
tis, demonstrating that NAFLD produces a morpholog-
ically covert proinflammatory microenvironment. Non-
specific injury of the male mouse liver frequently leads
to loss of sex-specific gene expression characterized
by transcriptional feminization.14 Accordingly, we
found a significant bias for sex-dependent transcrip-
tional alterations in the feminine direction in AB6F1
male mice with NAFLD. Feminine mRNA up-regulated
in the steatotic male liver included sulfotransferase 2a2
and Sult3a1, cytochrome P450 2b13 (Cyp2b13), lym-
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very long chain fatty acids–like 3, elastase-1 (pancre-
atic), and Cyp7b1. Although many of the metabolic
gene alterations in AB6F1 male mice were attributable
to hepatic feminization, sex-neutral gene products as-
sociated with metabolic function also were dysregu-
lated, including potassium channel T2, complement
factor D (adipsin), sulfotransferase 5A1, and insulin-
like growth factor binding protein 2. Taken together,
these data demonstrate that insulin resistance and
NAFLD are sufficient to invoke robust hepatic tran-
scriptional alterations related to inflammation, metabo-
lism, and sex-dependent liver function.
Parent-of-Origin Effects Not Linked to Known
Maternal or Paternal Genes
There are three known sources of parent-specific gene
expression: mitochondrial DNA, imprinted loci, and
sex-linked genes.21 Genes transcribed from mitochon-
drial DNA are maternal in origin, imprinted genes are
transcribed from a single parental allele, and sex chro-
mosomes are inherited in a parent-specific manner in
males. Because of the strong parent-of-origin effects in
AB F1 mice, we used qRT-PCR to interrogate genes
that met any of those criteria and were shown to be
differentially expressed by microarray. In addition, we
analyzed known parent-specific genes canonically as-
sociated with metabolism. Altogether, we assessed 4
mitochondrial DNA transcripts, 8 imprinted alleles, and
29 sex-linked genes in all male mice (Table 1). No
imprinted or mitochondrially encoded gene exhibited
differential expression between AB6F1 and B6AF1
mice (data not shown). In contrast, four X-linked genes
showed a positive correlation with NAFLD at one or
more time points. Of these, three were up-regulated at
9 and 15 months only (Frmpd3, Slc25a5, Tmsb4x),
suggesting an associative rather than causative rela-
tionship. The only X-linked gene up-regulated at all
time points in AB6F1 male mice was thyroxine-binding
globulin (TBG; Serpina7). Interestingly, this gene also
was increased in B6AF1 male mice with steatosis at 15
months. However, in all affected animals TBG up-reg-
Table 3. Comparison of Body Weight and Serum Insulin in A/J,
versus HF Diet
A/J B6.A
F BW LF diet 23.0  0.5 21.2 
F BW HF diet 31.7  1.4 30.0 
F BW % increase 38 42
M BW LF diet 29.6  0.7 26.7 
M BW HF diet 37.4  2.3 45.2 
M BW % increase 26 69
F insulin LF diet 1.2  0.3 1.2 
F insulin HF diet 1.9  0.7 2.4 
F insulin % increase 58 200
M insulin LF diet 2.4  0.3 1.6 
M insulin HF diet 4.7  0.3 9.6 
M insulin % increase 196 600Body weight (BW) presented as mean  SEM in grams. Serum insulin prese
F, female; M, male; HF, high fat; LF, low fat.ulation was modest (approximately twofold) and
showed no linear correlation with NAFLD severity (data
not shown). Further work will be required to determine
whether TBG contributes to the pathogenesis of insulin
resistance and NAFLD or is merely a bystander.
Viewed as a whole, our PCR survey failed to identify a
robust candidate among known uniparentally ex-
pressed genes to account for the significant parent-
specific metabolic phenotype in AB F1 male mice,
suggesting that the disease is polyfactorial and may
involve epigenetic mechanisms.
Sex- and Strain-Specific Responses to High-Fat
Diet in CSS and F1 Mice
Because we found some associations between X-linked
genes and the AB6F1 metabolic phenotype, we per-
formed a follow-up DIO study using sex chromosome
substitution strain B6.A mice. These animals were on a
B6 background except for an A/J-derived sex chromo-
some.22 Also included were AB F1 mice along with a
WT A/J control group. An additional control group of WT
B6 mice had to be excluded due to poor breeding kinet-
ics that resulted in insufficient numbers. In agreement
with the first study showing increased BW in AB F1
mice relative to the parent strains, B6AF1 and AB6F1
mice on the LF diet weighed significantly more than sex-
matched A/J and CSS strains (Table 3). All mice on the
HF diet weighed significantly more than sex- and strain-
matched animals on the LF diet. However, as a percent-
age of baseline body mass, CSS mice on the HF diet
gained more weight than A/J and F1 mice. This was
especially true of B6.AX male mice, which weighed less
than all other male groups on the LF diet but the same
as all but the A/J male mice on the HF diet. In A/J and
CSS mice, serum insulin levels increased in relative pro-
portion to body mass on the HF diet. In stark contrast,
insulin levels were significantly lower in B6AF1 and sig-
nificantly higher in AB6F1 male mice compared with CSS
mice despite nearly identical body weights (Figure 3). A
similar dichotomy between serum insulin and body mass
was observed in female F1 mice on the HF diet. Thus,
insulin resistance in F1 mice was regulated by distinct
B6.AY, B6AF1, and AB6F1 Female and Male Mice on a LF
B6.AY B6AF1 AB6F1
21.0  0.5 25.8  1.2 26.9  0.7
30.8  2.3 39.0  1.4 40.4  3.3
47 51 51
31.0  0.8 34.6  0.9 34.4  1.2
46.9  1.0 44.8  0.9 46.8  1.0
51 29 36
1.2  0.1 1.2  0.1 1.6  0.4
1.9  0.3 3.7  0.6 5.8  1.1
58 308 363
2.3  0.2 4.0  0.9 4.1  0.8










2.1nted as mean  SEM in nanograms per deciliter.
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gain. Female CSS and AB F1 but not A/J mice on the HF
diet exhibited mild-to-moderate macrovesicular steatosis
that did not vary by strain (data not shown). Male A/J
mice on the HF diet developed moderate patchy mac-
rovesicular steatosis, whereas CSS and F1 male mice
developed severe diffuse mixed hepatic steatosis (mean
fatty liver index  5/8; not shown). The proportion of
microvesicular-to-macrovesicular steatosis varied within
but not between groups. Viewed as a whole, these results
demonstrated that weight gain and hepatic steatosis in-
creased in tandem in response to the HF diet, whereas
insulin resistance was distinctly regulated in F1 male and
female mice. Indeed, B6AF1 mice were protected from
DIO-associated insulin resistance compared with CSS
mice, whereas AB6F1 mice displayed exaggerated hy-
perinsulinemia in response to caloric overload. This find-
ing suggests synergy in epistatic interactions between
parent-specific alleles in hybrid mice, resulting in a
marked shift in insulin sensitivity in a positive or negative
direction. Taken together, these results show that insulin
resistance is not directly correlated with increased body
mass and that additional genetic factors determine the
metabolic consequences of diet-induced obesity.
Insulin Resistance Invokes Adipogenic Transition of
Hepatocytes and Reactivates PKM2
Because of the remarkable histologic similarity between
steatotic hepatocytes and adipocytes (Figure 2E), we
wondered whether fatty liver was associated with molec-
ular changes characteristic of adipogenic transition.23 By
microarray and qRT-PCR, we found numerous examples
of adipocyte-associated genes that were up-regulated in
the livers of 9-month-old AB6F1 mice with NAFLD com-
pared with B6AF1 controls. As mesenchymal cells, adi-
Figure 3. Serum insulin and body weight comparison of A/J, B6.AX, B6.AY,
B6AF1, and AB6F1 mice on a HF diet. Note dissociation between body
weight and serum insulin levels in F1 mice compared with other groups. *P
 0.05, **P  0.1.pocytes express a number of canonical genes not typi-cally expressed in hepatocytes and other epithelial
tissues. Mesenchymal cell markers that were increased
in the livers of mice with NAFLD included vimentin, plate-
let-derived growth factor-, and collagen 3-1 (Figure
4A). In addition, there was up-regulation of more specific
adipocyte-associated gene products, including comple-
ment factor D (adipsin), fatty acid translocase (CD36),
fatty acid binding protein-4 (adipocyte), and peroxisome
proliferator–activated receptor- (PPAR-). Of singular
importance, the fetal isoform of pyruvate kinase, Pkm2,
was up-regulated nearly twofold in 9-month-old mice with
NAFLD. Functional protein expression was confirmed by
immunohistochemistry, where cytoplasmic and nuclear
PKM2 localization was visualized in neoplasms from
AB6F1 mice but not in normal B6AF1 liver (Figure 2A).
These results confirm that chronic hyperinsulinemia in-
vokes adipogenic transition of hepatocytes and invokes
metabolic pathways in an improper context that may con-
tribute to cellular transformation.
Insulin-Dependent Adipogenic Transition and
PKM2 Activation in Cultured Hepatocytes
To validate our in vivo findings and confirm that transcrip-
tional alterations reflected changes in parenchymal and
not accessory liver cells, we harvested, purified, and
cultured primary mouse hepatocytes. To ensure purity,
Figure 4. Primary hepatocyte isolation and culture. A: Flow cytometry dem-
onstrating less than 2% white blood cell contamination of enriched hepato-
cyte population; approximately 25% of hepatocytes labeled with anti-CD95/
Fas antibody. B: 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide
assay demonstrating strong trend (P  0.07) for increased viability of insulin-
supplemented cells versus dexamethasone alone after 4 days of culture.
Photomicrographs demonstrate organization of hepatocytes into crude
canaliculi, with increased clear (lipid) cytoplasmic vacuoles in insulin-sup-
plemented cells (original magnification, 1000). C: qRT-PCR of insulin-
supplemented primary hepatocytes (dark gray columns), especially on day 4
of culture, demonstrating increased expression of adipocyte-associated
genes, including vimentin, collagen 3-1, fatty acid translocase (CD36), and
PKM2, compared with nonsupplemented cells (light gray columns); these
genes also were up-regulated in AB6F1 versus B6AF1 male mice at 15 months
of age (black columns).
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which confirmed less than 2% contamination by white
blood cells (Figure 4A). Approximately 25% of the puri-
fied hepatocytes were positively labeled with an anti-
CD95/Fas antibody, in keeping with the known low level
of Fas surface expression in healthy mouse liver.24 To
ensure that our cultured cell population was primarily
hepatocytes, we performed qRT-PCR for albumin and
Apoa1 on freshly purified cells and found gene expres-
sion levels similar to those from intact mouse liver RNA
(not shown). Primary hepatocytes grown in the presence
of insulin exhibited greater viability after 4 days than did
those grown without insulin supplementation (Figure 4B).
Under all growth conditions, primary hepatocytes orga-
nized into crude canalicular structures; however, insulin-
supplemented cells exhibited clear cytoplasmic lipid-
storage vacuoles that were not evident in cells grown in
the presence of dexamethasone alone (Figure 4B). Insu-
lin supplementation to primary hepatocytes resulted
in up-regulation of many of the same adipocyte-associ-
ated gene products we documented in AB6F1 mice with
NAFLD, including but not limited to vimentin, collagen
3-1, fatty acid translocase (CD36), and Pkm2 (Figure
4C). Taken together, these results confirm that supra-
physiologic levels of insulin promote hepatocyte survival
and invoke activation of adipocyte-associated metabolic
pathways that may contribute to hepatocellular transfor-
mation.
Discussion
Beneath the current wave of obesity and T2D lurks a
larger swell of subclinical metabolic disease. In some
settings, up to 75% of individuals with NAFLD are non-
obese.25 Most diagnoses of NAFLD in the United States
are made in patients without previously identified risk
factors. Indeed, in a recent study, nearly half of clinically
healthy middle-aged adults in the United States exhibited
NAFLD by ultrasonography and/or biopsy.6 The potential
impact of covert insulin resistance and NAFLD on a na-
tional scale is unknown. However, it is noteworthy that
HCC continues to increase in the United States despite
steady or decreasing levels of viral hepatitis and alcohol-
ism. Indeed, NAFLD/NASH may one day surpass HCV
infection as the leading cause of liver cancer in the
United States.5
Because of the complex interactions between meta-
bolic disease and HCC, animal models are needed to
characterize the molecular events leading from steatosis
to cancer. We observed that male F1 offspring of A/J and
B6 mice developed spontaneous insulin resistance,
NAFLD, and HCC without obesity or T2D. Intriguingly, the
model exhibited strong parent-of-origin effects. AB6F1
but not B6AF1 mice developed early-onset insulin resis-
tance and NAFLD that progressed to HCC in many by
15 months of age. Despite this parent-of-origin-specific
inheritance, we found no strong associations with known
uniparentally expressed mitochondrial or imprinted
genes, although modest associations with some X-linked
genes were suggested. However, a follow-up DIO studyinvolving X and Y CSS mice confirmed no significant
phenotypic segregation by sex chromosome, although
B6.AX mice exhibited a leaner metabolic profile than
B6.AY mice on the LF diet. We concluded that the strong
parent-of-origin effects in AB F1 mice were specified
within the autosomal genome. Importantly, the DIO ex-
periment also revealed that obesity and insulin resistance
were regulated by distinct genetic mechanisms in hybrid
animals.
Diabetes is associated with an increased risk of HCC
in humans.26 In diabetic patients, treatment with sulfonyl-
urea or exogenous insulin increases HCC risk and wors-
ens tumor response to radioablation, whereas HCC pa-
tients taking the insulin-sensitizing drug metformin have
more favorable outcomes.27–29 This finding suggests a
direct role for insulin in liver tumor promotion. Because
insulin resistance in the absence of obesity or diabetes
was sufficient to promote HCC in AB6F1 mice, we inves-
tigated potential mechanisms of metabolic hepatocarci-
nogenesis. In mice with hyperinsulinemic NAFLD, hepato-
cytes underwent partial adipogenic transition characterized
morphologically by vacuolar metaplasia resembling WAT or
BAT. At the molecular level, canonical adipocyte gene
products were activated in steatotic hepatocytes, includ-
ing vimentin, adipsin, fatty acid translocase (CD36), fatty
acid–binding protein 4 (adipocyte), stearoyl-coA desatu-
rase 2, and PPAR-. This transcriptional profile was
largely recapitulated in insulin-supplemented but not in-
sulin-deprived primary mouse hepatocytes in vitro. Sup-
raphysiologic insulin exposure also promoted hepatocyte
survival in culture. Of special significance, we found that
excess insulin reactivated the fetal gene product PKM2 in
hepatocytes both in vitro and in vivo.
Complex metabolic traits are regulated polygeneti-
cally.30 Thus, our inability to pinpoint a single gene that
accounted for the parent-specific metabolic phenotype in
AB F1 mice was not surprising. Because neither paren-
tal inbred strain develops equivalent disease, polygen-
etic crosstalk rather than a single gene polymorphism
best explains the positive and negative heterosis ob-
served in B6AF1 and AB6F1 male mice, respectively.31
Although our genomic survey of F1 mice revealed a mod-
est association between NAFLD and X-linked thyroxine-
binding globulin, the follow-up DIO study with CSS mice
did not validate phenotypic segregation by sex chromo-
some. In the original description of B6.A CSS mice, it was
noted that 17 of the 23 CSS lines exhibited an intermedi-
ate obesity phenotype among parental inbred strains.21
Thus, metabolism is governed by multiple genes on an
array of different chromosomes. Recent work has re-
vealed important obesity-related quantitative trait loci on
chromosomes 6 and 17.32,33 Combining our results with
those from other laboratories, it seems clear that poly-
genic epistatic interactions, including those inherited in a
parent-specific manner, coordinately regulate insulin
sensitivity. These findings take on direct translational sig-
nificance in light of a recent study from Iceland showing
that parent-specific autosomal polymorphisms strongly
influence T2D risk in humans.34
In addition to its value as a genetic tool, the AB
mouse model has utility for addressing molecular mech-
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insulin resistance. For example, we observed that vacu-
olated hepatocytes in mice with hyperinsulinemic NAFLD
not only took on a morphologic appearance of WAT or
BAT but also expressed many genes classically associ-
ated with adipose tissue. These products included but
were not limited to adipsin, fatty acid translocase, fatty
acid–binding protein 4, vimentin, and PPAR-. The im-
portant role of insulin in adipogenic transition was con-
firmed by our in vitro experiments that recapitulated the
emergence of lipid vacuoles along with up-regulation of
adipogenic genes in primary mouse hepatocytes. More-
over, we confirmed that insulin extends hepatocyte sur-
vival and inhibits apoptosis. This may have in vivo signif-
icance because liver cells undergoing severe oxidative
stress in a proinflammatory microenvironment would be
prevented from entering apoptosis in the context of hy-
perinsulinemia, as shown experimentally in skeletal
muscle.35
A singularly important potential link among hyperinsu-
linemia, adipogenic transition, and HCC revealed by this
study was PKM2. Pyruvate kinases are critical enzymes
in glycolytic oxidative phosphorylation. There are four
pyruvate kinase isoforms: L, R, M1, and M2.36 The adult
liver is characterized by expression of the L-type iso-
form.37 In contrast, M2 is expressed predominantly dur-
ing embryogenesis in the fetal liver and other rapidly
dividing tissues.38 In contrast to the adult isoforms, PKM2
diverts glucose metabolism to an alternate pathway that
generates short carbon chains for molecular building
blocks needed by rapidly dividing cells.39 Aberrant ex-
pression of PKM2 is a common feature of cancers that
rely on aerobic glycolysis with lactate generation (War-
burg effect) to support rapid proliferation. Intriguingly,
PKM2 is activated normally in an insulin-dependent man-
ner during the programmed differentiation of NIH 3T3
cells from preadipocytes to adipocytes.40 It is possible
that insulin invokes adipogenic transition and Pkm2 ex-
pression in hepatocytes through similar mechanisms. Of
note, the only two adult mammalian tissues that ordinarily
express PKM2 are skeletal muscle and adipose tissue,
both of which are replicatively senescent.41,42 In contrast,
hepatocytes readily enter cell division with sufficient
prompting. It is tempting to speculate that insulin-di-
rected PKM2 reactivation in replication-competent cells,
such as hepatocytes, represents a significant proto-on-
cogenic event. If so, PKM2 inhibitors currently under de-
velopment for the treatment of established cancer also
may have utility for the prevention of HCC in patients with
insulin resistance and NAFLD.43 Further study will be
required to test this hypothesis.
In summary, we have introduced a novel mouse model
of primary insulin resistance, NAFLD, and HCC with
strong parent-of-origin effects. AB6F1 but not B6AF1
male mice develop spontaneous insulin resistance that
leads to severe NAFLD by 9 months and HCC by 15
months. Parent-specific inheritance in this model is poly-
genetic and encoded within the autosomal genome. We
have shown that insulin resistance is regulated indepen-
dently of diet-induced weight gain in AB F1 mice and
that hyperinsulinemia is associated with adipogenic tran-sition of hepatocytes. Among the adipocyte-associated
gene products in this program is PKM2, an anabolic
enzyme implicated in tumorigenesis and the Warburg
effect. Viewed as a whole, our study implicates the exis-
tence of autosomal parent-specific loci that may serve as
useful biomarkers for metabolic risk profiling and identi-
fies new potential targets to improve insulin sensitivity
and prevent NAFLD-associated HCC.
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